Poxel raises funds to advance diabetic drug development
Imeglimin is a new tetrahydrotriazine-containing class of oral anti- diabetics, the Gliminsand, and is being developed through phase II trials as a monotherapy and as an add-on therapy
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.